ACET — Adicet Bio, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1720580 ·
Last close
$8.83
Market Cap
$82.54M
52W High
$9.47
52W Low
$6.05
ADV30
91,487
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -21,570,000 | -20,244,000 | 169,382,000 | 36,245,000 | 29,317,000 |
| Dec 2025 | 0 | — | -31,886,000 | -30,516,000 | 192,355,000 | 38,918,000 | 33,145,000 |
| Sep 2025 | 0 | — | -27,952,000 | -26,856,000 | 140,479,000 | 29,099,000 | 31,337,000 |
| Jun 2025 | 0 | — | -32,392,000 | -31,217,000 | 162,972,000 | 34,720,000 | 29,600,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-91,339,000
Investing CF
$24,133,000
Financing CF
$75,284,000
CapEx
$-1,785,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-14.90
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-634,941,000
Inventory
—
Receivables
$405,000
ST Investments
$101,347,000
EBIT TTM
$-108,774,000
Pretax Income TTM
$-108,833,000
Interest Exp TTM
$59,000
Analysts
6
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -122,114,000 | -116,803,000 | 192,355,000 | 33,145,000 | — | -95,246,000 |
| Dec 2024 | 0 | -127,615,000 | -117,122,000 | 220,219,000 | 33,610,000 | — | -92,378,000 |
| Dec 2023 | 0 | -132,576,000 | -142,658,000 | 207,295,000 | 37,120,000 | — | -93,717,000 |
| Dec 2022 | 24,990,000 | -72,551,000 | -69,790,000 | 330,690,000 | 38,352,000 | — | -44,765,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.19
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GOSS | Gossamer Bio, Inc. | $82.96M | $0.17 | — |
| RNTX | Rein Therapeutics, Inc. | $83.83M | $0.98 | — |
| ACRV | Acrivon Therapeutics, Inc. | $83.89M | $1.96 | — |
| ZOMDF | Zomedica Corp. | $84.18M | $0.09 | — |
| TELO | Telomir Pharmaceuticals, Inc. | $84.59M | $1.23 | — |
News headlines (Yahoo Finance, 1h cache)
Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year?
2026-07-01 13:40 · Yahoo
Harbour BioMed Appoints Dr. Lloyd Klickstein as Scientific Advisor for Immunology
2026-06-29 01:27 · Yahoo
Adicet Bio Teases Autoimmune Data Catalysts, PSMA Plans at Jefferies Conference
2026-06-04 18:04 · Yahoo
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
2026-05-28 13:40 · Yahoo
Wall Street Analysts Believe Adicet Bio (ACET) Could Rally 319.64%: Here's is How to Trade
2026-05-25 13:55 · Yahoo
Adicet Bio (ACET) Upgraded to Buy: Here's Why
2026-03-24 16:00 · Yahoo
MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
2025-11-12 21:05 · Yahoo
Are Medical Stocks Lagging Exact Sciences (EXAS) This Year?
2025-10-07 13:40 · Yahoo
Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know
2025-09-30 16:00 · Yahoo
MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio
2025-08-11 13:46 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.